Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.5.0.2
Segment Reporting (Tables)
9 Months Ended
Aug. 31, 2016
Segment Reporting [Abstract]  
Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense) and other comprehensive income for the three months and nine months ended August 31, 2016:

 

     For the three months
ended August 31,
2016
     For the nine months
ended August 31,
2016
 

Net revenue

     

Umbilical cord blood and cord tissue stem cell service

   $ 6,243,803       $ 16,970,939   

Prepacyte®-CB

     88,135         286,253   
  

 

 

    

 

 

 

Total net revenue

   $ 6,331,938       $ 17,257,192   
  

 

 

    

 

 

 

Cost of sales

     

Umbilical cord blood and cord tissue stem cell service

   $ 1,482,900       $ 4,073,293   

Prepacyte®-CB

     68,331         257,329   
  

 

 

    

 

 

 

Total cost of sales

   $ 1,551,231       $ 4,330,622   
  

 

 

    

 

 

 

Depreciation and amortization

     

Umbilical cord blood and cord tissue stem cell service

   $ 27,310       $ 84,542   

Prepacyte®-CB

     12,436         38,624   
  

 

 

    

 

 

 

Total depreciation and amortization

   $ 39,746       $ 123,166   
  

 

 

    

 

 

 

Operating (loss) income

     

Umbilical cord blood and cord tissue stem cell service

   $ 808,254       $ 1,864,325   

Prepacyte®-CB

     (1,870,329      (1,887,594
  

 

 

    

 

 

 

Total operating loss

   $ (1,062,075    $ (23,269
  

 

 

    

 

 

 

Interest expense

     

Umbilical cord blood and cord tissue stem cell service

   $ 199,439       $ 781,971   

Prepacyte®-CB

     —           22,265   
  

 

 

    

 

 

 

Total interest expense

   $ 199,439       $ 804,236   
  

 

 

    

 

 

 

 

The following table shows the assets by segment as of August 31, 2016 and November 30, 2015:

 

     As of August 31,
2016
     As of November 30,
2015
 

Assets

     

Umbilical cord blood and cord tissue stem cell service

   $ 16,755,419       $ 16,697,621   

Prepacyte®-CB

     786,866         2,800,325   
  

 

 

    

 

 

 

Total assets

   $ 17,542,285       $ 19,497,946